Amendment: Shineco Inc. filed SEC Form 8-K: Financial Statements and Exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES AND EXCHANGE ACT OF 1934
Date
of report (date of earliest event reported): May 14, 2025 (
(Exact name of registrant as specified in its charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices)
Registrant’s
telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each Class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Explanatory Note
As previously disclosed in its Current Report on Form 8-K filed with the Securities and Exchange Commission on May 13, 2025 (the “Original Form 8-K”), on May 12, 2025 (the “Closing Date”), Shineco Life Science Group Hong Kong Co., Limited (“Shineco Life Science”), a subsidiary of Shineco, Inc. (the “Company”), closed an acquisition of 75% of the equity interests in FuWang (HK) International Company Limited, a company limited by shares incorporated in Hong Kong (“FuWang (HK)”), pursuant to the stock purchase agreement (the “SPA”) dated March 20, 2025 with Yi Yang, the only shareholder of FuWang (HK) (the “Seller”). On or prior to the Closing Date, the closing conditions as set forth in the SPA were satisfied or otherwise waived by the parties thereto, and the Seller has transferred 75% of the equity interests in FuWang (HK) to Shineco Life Science; therefore, FuWang (HK) became a direct subsidiary of Shineco Life Science.
This Amendment to the Original Form 8-K is being filed to amend and supplement the Original Form 8-K, the sole purpose of which is to provide the financial statements required by Item 9.01(a), which were excluded from the Original Form 8-K and are filed as exhibits hereto and are incorporated herein by reference. All other items in the Original Form 8-K remain the same.
| 2 |
Item 9.01 Financial Statements and Exhibits
(a) Financial Statements of Businesses Acquired
The audited financial statements of FuWang (HK), which comprise the balance sheets as of June 30, 2024 and 2023, the related statements of operations, shareholders’ equity, and cash flows for the fiscal years ended June 30, 2024 and 2023, and the related notes to the audited financial statements, and the unaudited financial statements for the period ended December 31, 2024, are filed as Exhibit 99.1 and Exhibit 99.2 hereto and incorporated by reference herein.
(b) Pro Forma Financial Information
The unaudited pro forma condensed combined (i) balance sheet as of and for the six-month period ended December 31, 2024, and (ii) income statement for the period ended December 31, 2024, and (iii) the related notes thereto, are filed as Exhibit 99.3 hereto and incorporated by reference herein.
(d) Exhibits
| Exhibit No. | Description | |
| 23.1 | Consent of Tang Xin CPAs, Independent Registered Public Accounting Firm | |
| 99.1 | Audited financial statements of FuWang (HK) as of and for the fiscal years ended June 30, 2024 and 2023 | |
| 99.2 | Unaudited financial statements of FuWang (HK) for the period ended December 31, 2024 | |
| 99.3 | Unaudited pro forma condensed combined financial statements and the related notes thereto | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101). |
| 3 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Shineco Inc. | ||
| Date: May 14, 2025 | By: | /s/ Jennifer Zhan |
| Jennifer Zhan, Chief Executive Officer | ||
| 4 |